微小RNA：胆管癌中新的调节分子与生物标志物

doi:10.3760/cma.j.issn.1673-422X.2016.11.017

国际肿瘤学杂志 ›› 2016, Vol. 43 ›› Issue (11): 865-867.doi: 10.3760/cma.j.issn.1673-422X.2016.11.017

微小RNA：胆管癌中新的调节分子与生物标志物

吴雄波，安方梅，占强

214023南京医科大学附属无锡人民医院消化内科

收稿日期:2016-04-05 出版日期:2016-11-08 发布日期:2016-11-02
通讯作者: 占强，Email: zhanq33@163.com E-mail:占强，Email: zhanq33@163.com
基金资助:
国家自然科学基金（81502038）；江苏省自然科学基金（BK2012098）

MicroRNAs： the emerging regulatory molecules and biomarkers of cholangiocarcinoma

Wu Xiongbo, An Fangmei, Zhan Qiang

Department of Gastroenterology, Wuxi People′s Hospital Affiliated to Nanjing Medical University, Wuxi 214023, China

Received:2016-04-05 Online:2016-11-08 Published:2016-11-02
Contact: 占强，Email: zhanq33@163.com E-mail:占强，Email: zhanq33@163.com
Supported by:
National Natural Science Foundation of China (81502038); Natural Science Foundation of Jiangsu Province of China (BK2012098)

摘要/Abstract

摘要： 微小RNA（miRNA）与胆管癌（CCA）的发生发展、浸润、转移和预后密切相关。CCA细胞中异常表达的miRNA在调控细胞遗传变异、细胞周期、浸润转移能力及其凋亡过程中起重要作用，有望作为CCA早期诊断、预后判断的生物学标志物及治疗靶点。

关键词: 胆管肿瘤, 微RNAs, 生物学标记

Abstract: MicroRNAs (miRNAs) are closely associated with the development, invasion, metastasis and prognosis of cholangiocarcinoma (CCA). The abnormal expressions of miRNA play important roles in regulating the genetic variation, cell cycle, invasion and metastasisability and apoptosis of CCA. MiRNAs are hopeful for being used as the biological markers of early diagnosis, prognosis and treatment target.

Key words: Bile duct neoplasms, MicroRNAs, Biological markers

吴雄波，安方梅，占强. 微小RNA：胆管癌中新的调节分子与生物标志物[J]. 国际肿瘤学杂志, 2016, 43(11): 865-867.

Wu Xiongbo, An Fangmei, Zhan Qiang. MicroRNAs： the emerging regulatory molecules and biomarkers of cholangiocarcinoma[J]. Journal of International Oncology, 2016, 43(11): 865-867.

参考文献

［1］ Braconi C, Huang N, Patel T. MicroRNAdependent regulation of DNA methyltransferase1 and tumor suppressor gene expression by interleukin 6 in human malignant cholangiocytes［J］. Hepatology, 2010, 51(3): 881-890. DOI: 10.1002/hep.23381. ［2］ An F, Yamanaka S, Allen S, et al. Silencing of miR370 in human cholangiocarcinoma by allelic loss and interleukin 6 induced maternal to paternal epigenotype Switch［J］. PLoS One, 2012, 7(10): e45606. DOI: 10.1371/journal.pone.0045606. ［3］ Bueno MJ, Malumbres M. MicroRNAs and the cell cycle［J］. Biochim Biophys Acta, 2011, 1812(5): 592-601. DOI: 10.1016/j.bbadis.2011.02.002. ［4］ Zhong XY, Yu JH, Zhang WG, et al. MicroRNA421 functions as an oncogenic miRNA in biliary tract cancer through downregulating farnesoid X receptor expression［J］. Gene, 2012, 493(1): 44-51. DOI: 10.1016/j.gene.2011.11.028. ［5］ Olaru AV, Ghiaur G, Yamanaka S, et al. MicroRNA downregulated in human cholangiocarcinoma control cell cycle through multiple targets involved in the G1/S checkpoint［J］. Hepatology, 2011, 54(6): 20892098. DOI: 10.1002/hep.24591. ［6］ Yamanaka S, Campbell NR, An F, et al. Coordinated effects of microRNA494 induce G2/M arrest in human cholangiocarcinoma［J］. Cell Cycle, 2012, 11(14): 2729-2738. DOI: 10.4161/cc.21105. ［7］ An F, Olaru AV, Mezey E, et al. MicroRNA224 induces G1/S checkpoint release in liver cancer［J］. J Clin Med, 2015, 4(9): 17131728. DOI: 10.3390/jcm4091713. ［8］ Namwat N, Chusorn P, Loilome W, et al. Expression profiles of oncomir miR21 and tumor suppressor let7a in the progression of opisthorchiasisassociated cholangiocarcinoma［J］. Asian Pac J Cancer Prev, 2012, 13(Suppl): 65-69. ［9］ Chang Y, Liu C, Yang J, et al. MiR-20a triggers metastasis of gallbladder carcinoma［J］. J Hepatol, 2013, 59(3): 518-527. DOI: 10.1016/j.jhep.2013.04.034. ［10］ Zeng B, Li Z, Chen R, et al. Epigenetic regulation of miR124 by hepatitis C virus core protein promotes migration and invasion of intrahepatic cholangiocarcinoma cells by targeting SMYD3［J］. FEBS Lett, 2012, 586(19): 32713278. DOI: 10.1016/j.febslet.2012.06.049. ［11］ Qiu YH, Wei YP, Shen NJ, et al. miR204 inhibits epithelial to mesenchymal transition by targeting slug in intrahepatic cholangiocarcinoma cells［J］. Cell PhysiolBiochem, 2013, 32(5): 13311341. DOI: 10.1159/000354531. ［12］ Selaru FM, Olaru AV, Kan T, et al. MicroRNA21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3［J］. Hepatology, 2009, 49(5): 1595-1601. DOI: 10.1002/hep.22838. ［13］ Wang Q, Tang H, Yin S, et al. Downregulation of microRNA-138 enhances the proliferation, migration and invasion of cholangiocarcinoma cells through the upregulation of RhoC/p-ERK/MMP-2/MMP9［J］. Oncol Rep, 2013, 29(5): 20462052. DOI: 10.3892/or.2013.2304. ［14］ Peng F, Jiang J, Yu Y, et al. Direct targeting of SUZ12/ROCK2 by miR200b/c inhibits cholangiocarcinoma tumourigenesis and metastasis［J］. Br J Cancer, 2013, 109(12): 3092-3104. DOI: 10.1038/bjc.2013.655. ［15］李知翰, 张西亮, 汪伟. 微小RNA126与血管内皮生长因子在胃癌中的表达及意义［J］. 国际肿瘤学杂志, 2015, 42(12): 900-902. DOI: 10.3760/cma.j.issn.1673-422X.2015.12.005. ［16］ Iwaki J, Kikuchi K, Mizuguchi Y, et al. MiR376c downregulation accelerates EGFdependent migration by targeting GRB2 in the HuCCT1 human intrahepatic cholangiocarcinoma cell line［J］. PLoS One, 2013, 8(7): e69496. DOI: 10.1371/journal.pone.0069496. ［17］ Si ML, Zhu S, Wu H, et al. miR21mediated tumor growth［J］. Oncogene, 2007, 26(19): 2799-2803. DOI: 10.1038/sj.onc.1210083. ［18］ Razumilava N, Bronk SF, Smoot RL, et al. miR25 targets TNFrelated apoptosis inducing ligand (TRAIL) death receptor4 and promotes apoptosis resistance in cholangiocarcinoma［J］. Hepatology, 2012, 55(2): 465475. DOI: 10.1002/hep.24698. ［19］ Hu C, Huang F, Deng G, et al. miR31 promotes oncogenesis in intrahepatic cholangiocarcinoma cells via the direct suppression of RASA1［J］. Exp Ther Med, 2013, 6(5): 1265-1270. DOI: 10.3892/etm.2013.1311. ［20］ Mott JL, Kobayashi S, Bronk SF, et al. mir29 regulates Mcl1 protein expression and apoptosis［J］. Oncogene, 2007, 26(42): 6133-6140. DOI: 10.1038/sj.onc.1210436. ［21］ Meng F, Henson R, Lang M, et al. Involvement of human microRNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines［J］. Gastroenterology, 2006, 130(7): 2113-2129. DOI: 10.1053/j.gastro.2006.02.057. ［22］ Bernuzzi F, Marabita F, Lleo A, et al. Serum microRNAs as novel biomarkers for primary sclerosing cholangitis and cholangiocarcinoma［J］. ClinExpImmunol, 2016, 185(1): 61-71. DOI: 10.1111/cei.12776. ［23］唐秋, 胡巧英. 肿瘤标志物循环微小RNA的临床研究现状［J］. 国际肿瘤学杂志, 2015, 42(11): 832834. DOI: 10.3760/cma.j.issn.1673422X.2015.11.009. ［24］ Shigehara K, Yokomuro S, Ishibashi O, et al. Realtime PCRbased analysis of the human bile microRNAome identifies miR9 as a potential diagnostic biomarker for biliary tract cancer［J］. PLoS One, 2011, 6(8): e23584. DOI: 10.1371/journal.pone.0023584. ［25］ Kawahigashi Y, Mishima T, Mizuguchi Y, et al. MicroRNA profiling of human intrahepatic cholangiocarcinoma cell lines reveals biliary epithelial cellspecific microRNAs［J］. J Nippon Med Sch, 2009, 76(4): 188-197. ［26］ Collins AL, Wojcik S, Liu J, et al. A differential microRNA profile distinguishes cholangiocarcinoma from pancreatic adenocarcinoma［J］. Ann SurgOncol, 2014, 21(1): 133-138. DOI: 10.1245/s10434-013-3240-y. ［27］黄敏丹, 吴雄波, 曹慧, 等. 血清miR224调控胆管上皮癌细胞的侵袭及转移作用［J］. 中华肝脏病杂志, 2015, 23(10): 748-753. DOI: 10.3760/cma.j.issn.1007-3418.2015.10.008. ［28］ Peng HH, Zhang YD, Gong LS, et al. Increased expression of microRNA335 predicts a favorable prognosis in primary gallbladder carcinoma［J］. Onco Targets Ther, 2013, 6: 1625-1630. DOI: 10.2147/OTT.S53030. ［29］ Jin K, Xiang Y, Tang J, et al. miR34 is associated with poor prognosis of patients with gallbladder cancer through regulating telomere length in tumor stem cells［J］. TumourBiol, 2014, 35(2): 15031510. DOI: 10.1007/s132770131207z. ［30］ Mcnally ME, Collins A, Wojcik SE, et al. Concomitant dysregulation of microRNAs miR-151-3p and miR-126 correlates with improved survival in resected cholangiocarcinoma［J］. HPB (Oxford), 2013, 15(4): 260-264. DOI: 10.1111/j.1477-2574.2012.00523.x. ［31］ Hummel R, Hussey DJ, Haier J. MicroRNAs: predictors and modifiers of chemo and radiotherapy in different tumour types［J］. Eur J Cancer, 2010, 46(2): 298-311. DOI: 10.1016/j.ejca.2009.10.027. ［32］ Okamoto K, Miyoshi K, Murawaki Y. miR29b, miR-205 and miR-221 enhance chemosensitivity to gemcitabine in HuH28 human cholangiocarcinoma cells［J］. PLoS One, 2013, 8(10): e77623. DOI: 10.1371/journal.pone.0077623.

[1]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛. 索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.
[2]	龚艳, 陈洪雷. 微RNA调控卵巢癌顺铂耐药的机制研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 186-190.
[3]	黄辉, 丁江华. 靶向FGFR2治疗晚期胆管癌的研究进展[J]. 国际肿瘤学杂志, 2023, 50(9): 569-573.
[4]	全祯豪, 徐飞鹏, 黄哲, 黄先进, 陈日红, 孙开裕, 胡旭, 林琳. 沉默lncRNA FTX通过miR-22-3p/NLRP3炎症体通路抑制胃癌细胞增殖[J]. 国际肿瘤学杂志, 2023, 50(4): 202-207.
[5]	周仁邦, 张仲传, 许志远, 朱勋兵. miR-219a-5p通过负调控HMGA2抑制骨肉瘤U2OS细胞增殖、侵袭和迁移[J]. 国际肿瘤学杂志, 2022, 49(4): 193-198.
[6]	金嘉会, 陈存海, 马学真. 放射相关miRNA在乳腺癌放疗中的作用[J]. 国际肿瘤学杂志, 2022, 49(12): 735-738.
[7]	井文君, 赵文文, 冯青青, 赵文飞, 赵丽丽, 张雪, 魏红梅. miR-34家族用于胃癌治疗的分子基础及临床前景[J]. 国际肿瘤学杂志, 2022, 49(11): 681-686.
[8]	罗丽云, 赖灿辉, 梁仁佩, 杨爱武, 林志敏. 晚期胃癌中miR-524-5p与SOX9表达的相关性及其对化疗疗效和预后的影响[J]. 国际肿瘤学杂志, 2022, 49(1): 45-50.
[9]	刘佩, 蒲嘉泽, 黄雯, 汪斐. 吉非替尼敏感与耐药NSCLC患者miR-200c、miR-19a、miR-155表达差异及其对患者预后的影响[J]. 国际肿瘤学杂志, 2021, 48(7): 409-414.
[10]	王阳, 刘芊, 龙辉, 吴清明. 结直肠癌标志物粪便检测的研究现状[J]. 国际肿瘤学杂志, 2021, 48(7): 441-444.
[11]	程一鸣, 李刚, 王振明, 吕倩文, 李世荣. 血清miR-196a-5p、miR-105-5p在良恶性肺结节鉴别诊断中的价值[J]. 国际肿瘤学杂志, 2021, 48(5): 282-286.
[12]	邓波儿, 孔为民. 子宫内膜癌的表观遗传学研究进展[J]. 国际肿瘤学杂志, 2021, 48(3): 184-188.
[13]	李炳亮, 杨娅, 黄英丽, 司文, 李兴伟, 张元民, 卞继超, 陈语. miR-20a-5p靶向KDM6B对骨肉瘤细胞增殖、迁移和侵袭能力的影响[J]. 国际肿瘤学杂志, 2021, 48(2): 65-73.
[14]	何苗, 范奎, 曹芳. 表观遗传与肺癌耐药[J]. 国际肿瘤学杂志, 2021, 48(10): 622-626.
[15]	张敏, 周丽娜, 徐姗姗, 陈骏. 肿瘤免疫治疗相关预测生物标志物研究进展[J]. 国际肿瘤学杂志, 2020, 47(8): 487-491.

微小RNA：胆管癌中新的调节分子与生物标志物

MicroRNAs： the emerging regulatory molecules and biomarkers of cholangiocarcinoma

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价